Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 10/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 5/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 4/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | SHBG | P04278 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | KCNA1 | Q09470 | 1/20 | 1.00 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 1.00 |
| ▸ | FNTA | P49354 | 5/20 | 0.78 |
| ▸ | FNTB | P49356 | 5/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.78 |
| ▸ | BLM | P54132 | 2/20 | 0.78 |
| ▸ | MEN1 | O00255 | 2/20 | 0.78 |
| ▸ | AR | P10275 | 1/20 | 0.78 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cortisone SCHEMBL13332835 | 1.00 | HSD17B10 (1.00) | HSD17B10NR3C1SERPINA6TSHRLMNA | |
| Cortisone SCHEMBL4888 | 1.00 | HSD17B10 (1.00) | HSD17B10NR3C1SERPINA6TSHRLMNA | |
| Cortisone SCHEMBL10089738 | 1.00 | HSD17B10 (1.00) | HSD17B10NR3C1SERPINA6TSHRLMNA | |
| Cortisone SCHEMBL6535496 | 1.00 | HSD17B10 (1.00) | HSD17B10NR3C1SERPINA6TSHRLMNA | |
| Cortisone SCHEMBL9926754 | 1.00 | HSD17B10 (1.00) | HSD17B10NR3C1SERPINA6TSHRLMNA | |
| Cortisone SCHEMBL5082082 | 0.99 | HSD17B10 (0.98) | HSD17B10NR3C1SERPINA6TSHRLMNA | |
| Cortisone SCHEMBL28542114 | 0.99 | HSD17B10 (0.98) | HSD17B10NR3C1SERPINA6TSHRLMNA | |
| Cortisone SCHEMBL28537808 | 0.99 | HSD17B10 (0.98) | HSD17B10NR3C1SERPINA6TSHRLMNA | |
| Cortisone SCHEMBL5082086 | 0.99 | HSD17B10 (0.98) | HSD17B10NR3C1SERPINA6TSHRLMNA | |
| Cortisone SCHEMBL27538706 | 0.99 | HSD17B10 (0.98) | HSD17B10NR3C1SERPINA6TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3350313-A1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | Agency For Science, Technology And Research (A*star) (SG) | 2018-07-25 | — | — | EP | claimed |
| WO-2017048193-A1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) (SG) | 2017-03-23 | — | — | WO | claimed |
| EP-4536193-A1 | COMPOSITIONS | Estrenue Pty Ltd (AU) | 2025-04-16 | — | — | EP | disclosed |
| WO-2023235935-A1 | COMPOSITIONS | •ESTRENUE PTY LTD (AU) | 2023-12-14 | — | — | WO | disclosed |
| US-20140309398-A1 | OLIGOMER-CORTICOSTEROID CONJUGATES | NEKTAR THERAPEUTICS | 2014-10-16 | — | — | US | disclosed |
| US-8796248-B2 | Oligomer-corticosteroid conjugates | NEKTAR THERAPEUTICS (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796248-B2 | Oligomer-corticosteroid conjugates | NEKTAR THERAPEUTICS (US) | 2014-08-05 | — | — | US | disclosed |
| US-20100286107-A1 | Oligomer-Corticosteroid Conjugates | NEKTAR THERAPEUTICS (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100286107-A1 | Oligomer-Corticosteroid Conjugates | NEKTAR THERAPEUTICS (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100056488-A1 | CORTICOSTEROID CONJUGATES AND USES THEREOF | THE MCLEAN HOSPITAL CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056488-A1 | CORTICOSTEROID CONJUGATES AND USES THEREOF | THE MCLEAN HOSPITAL CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
| WO-2009045539-A2 | OLIGOMER-CORTICOSTEROID CONJUGATES | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2008137740-A1 | FULVENE AND FULVALENE ANALOGS AND THEIR USE IN TREATING CANCERS | EMORY UNIVERSITY (US) | 2008-11-13 | — | — | WO | disclosed |
| US-20080275016-A1 | For drug resistant cancers; antiinflammatory agents;degenerative or vascular diseases; blocking nitrogen oxide so growth of tumors is suppressed | U.S. GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS, THE | 2008-11-06 | — | — | US | disclosed |
| US-20080275016-A1 | For drug resistant cancers; antiinflammatory agents;degenerative or vascular diseases; blocking nitrogen oxide so growth of tumors is suppressed | U.S. GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS, THE | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056488-A1 | CORTICOSTEROID CONJUGATES AND USES THEREOF | NR3C1, NR3C2, C3AR1 | HSD17B10 237/4885NR3C1 1/4885SERPINA6 6/4885 |
| US-20100286107-A1 | Oligomer-Corticosteroid Conjugates | SERPINA6, NR3C2, NR3C1 | HSD17B10 912/4885NR3C1 3/4885SERPINA6 1/4885 |
| US-20140309398-A1 | OLIGOMER-CORTICOSTEROID CONJUGATES | SERPINA6, NR3C1, NR3C2 | HSD17B10 711/4885NR3C1 2/4885SERPINA6 1/4885 |
| US-20080275016-A1 | For drug resistant cancers; antiinflammatory agents;degenerative or vascular diseases; blocking nitrogen oxide so growth of tumors is suppressed | NOX1, NOX3, ROS1 | HSD17B10 3682/4885NR3C1 52/4885SERPINA6 1737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.